Boston Scientific (0HOY) Share Forecast & Price Target

Compare

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0HOY Analyst Ratings

Strong Buy

22 Buy

0 Hold

0 Sell

Based on 22 analysts giving stock ratings to

Boston

Scientific

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0HOY Stock 12 Month Forecast

Average Price Target

$108.38

▲(50.99% Upside)

Based on 22 Wall Street analysts offering 12 month price targets for Boston Scientific in the last 3 months. The average price target is $108.38 with a high forecast of $132.00 and a low forecast of $94.00. The average price target represents a 50.99% change from the last price of $71.78.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"75":"$75","104":"$104","133":"$133","89.5":"$89.5","118.5":"$118.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":132,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$132.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":108.38095238095238,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$108.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":94,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$94.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[75,89.5,104,118.5,133],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,76.31,80.59384615384616,84.87769230769231,89.16153846153847,93.44538461538463,97.72923076923078,102.01307692307692,106.29692307692308,110.58076923076923,114.86461538461539,119.14846153846155,123.43230769230769,127.71615384615384,{"y":132,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,76.31,78.77699633699633,81.24399267399268,83.71098901098901,86.17798534798536,88.64498168498169,91.11197802197802,93.57897435897436,96.0459706959707,98.51296703296703,100.97996336996337,103.4469597069597,105.91395604395603,{"y":108.38095238095238,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,76.31,77.67076923076924,79.03153846153846,80.3923076923077,81.75307692307692,83.11384615384615,84.47461538461539,85.83538461538461,87.19615384615385,88.55692307692308,89.9176923076923,91.27846153846154,92.63923076923076,{"y":94,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":102.412,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.62,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.598,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.64,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.156,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.18,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.39,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.83,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.852,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.405,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.89,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.1,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 66,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.31,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$132.00

Average Price Target$108.38

Lowest Price Target$94.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Danielle Antalffy

UBS

$120

Buy

67.18%

Upside

Reiterated

03/05/26

UBS Sticks to Their Buy Rating for Boston Scientific (BSX)

Josh Jennings

TD Cowen

$100

Buy

39.31%

Upside

Reiterated

03/04/26

Boston Scientific: Share Price Weakness Creates Opportunity Amid Strong Growth Outlook and Margin Expansion

Travis Steed

Bank of America Securities

$105

Buy

46.28%

Upside

Reiterated

03/03/26

Boston Scientific: Near-Term EP Reset but 2027 Growth Drivers Support Buy Rating

Marie Thibault

BTIG

$110

Buy

53.25%

Upside

Reiterated

02/20/26

BTIG Reaffirms Their Buy Rating on Boston Scientific (BSX)

Michael Matson

Needham

$97

Buy

35.14%

Upside

Reiterated

02/18/26

Boston Scientific: BUY on WATCHMAN Growth Optionality and Favorable CHAMPION-AF Risk/Reward Setup

William Plovanic

Canaccord Genuity

$112→$109

Buy

51.85%

Upside

Reiterated

02/17/26

Boston Scientific price target lowered to $109 from $112 at CanaccordBoston Scientific price target lowered to $109 from $112 at Canaccord

Robbie Marcus

J.P. Morgan

―

Buy

―

Reiterated

02/16/26

Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX), Neurocrine (NASDAQ: NBIX) and Dexcom (NASDAQ: DXCM)

Matt Miksic

Barclays

$124

Buy

72.75%

Upside

Reiterated

02/12/26

Barclays Reaffirms Their Buy Rating on Boston Scientific (BSX)

Rick Wise

Stifel Nicolaus

$110

Buy

53.25%

Upside

Reiterated

02/12/26

Analysts Offer Insights on Healthcare Companies: Soligenix (NASDAQ: SNGX) and Boston Scientific (NYSE: BSX)

Joanne Wuensch

Citi

$102

Buy

42.10%

Upside

Reiterated

02/08/26

Boston Scientific: Multi-Year Double-Digit Growth Outlook Makes Share Pullback a Buy Opportunity

Richard Newitter

Truist Financial

$120→$95

Buy

32.35%

Upside

Reiterated

02/05/26

Analysts Conflicted on These Healthcare Names: Eli Lilly & Co (NYSE: LLY), McKesson (NYSE: MCK) and Boston Scientific (NYSE: BSX)

Anthony Petrone

Mizuho Securities

$140→$115

Buy

60.21%

Upside

Reiterated

02/05/26

Boston Scientific price target lowered to $115 from $140 at MizuhoBoston Scientific price target lowered to $115 from $140 at Mizuho

David Rescott

Robert W. Baird

$118→$101

Buy

40.71%

Upside

Reiterated

02/05/26

Boston Scientific price target lowered to $101 from $118 at BairdBoston Scientific price target lowered to $101 from $118 at Baird

Larry Biegelsen

Wells Fargo

$125→$94

Buy

30.96%

Upside

Reiterated

02/05/26

Wells Fargo Sticks to Its Buy Rating for Boston Scientific (BSX)

Vijay Kumar

Evercore ISI

$112→$96

Buy

33.74%

Upside

Reiterated

02/05/26

Boston Scientific price target lowered to $96 from $112 at Evercore ISIBoston Scientific price target lowered to $96 from $112 at Evercore ISI

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Danielle Antalffy

UBS

$120

Buy

67.18%

Upside

Reiterated

03/05/26

UBS Sticks to Their Buy Rating for Boston Scientific (BSX)

Josh Jennings

TD Cowen

$100

Buy

39.31%

Upside

Reiterated

03/04/26

Boston Scientific: Share Price Weakness Creates Opportunity Amid Strong Growth Outlook and Margin Expansion

Travis Steed

Bank of America Securities

$105

Buy

46.28%

Upside

Reiterated

03/03/26

Boston Scientific: Near-Term EP Reset but 2027 Growth Drivers Support Buy Rating

Marie Thibault

BTIG

$110

Buy

53.25%

Upside

Reiterated

02/20/26

BTIG Reaffirms Their Buy Rating on Boston Scientific (BSX)

Michael Matson

Needham

$97

Buy

35.14%

Upside

Reiterated

02/18/26

Boston Scientific: BUY on WATCHMAN Growth Optionality and Favorable CHAMPION-AF Risk/Reward Setup

William Plovanic

Canaccord Genuity

$112→$109

Buy

51.85%

Upside

Reiterated

02/17/26

Boston Scientific price target lowered to $109 from $112 at CanaccordBoston Scientific price target lowered to $109 from $112 at Canaccord

Robbie Marcus

J.P. Morgan

―

Buy

―

Reiterated

02/16/26

Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX), Neurocrine (NASDAQ: NBIX) and Dexcom (NASDAQ: DXCM)

Matt Miksic

Barclays

$124

Buy

72.75%

Upside

Reiterated

02/12/26

Barclays Reaffirms Their Buy Rating on Boston Scientific (BSX)

Rick Wise

Stifel Nicolaus

$110

Buy

53.25%

Upside

Reiterated

02/12/26

Analysts Offer Insights on Healthcare Companies: Soligenix (NASDAQ: SNGX) and Boston Scientific (NYSE: BSX)

Joanne Wuensch

Citi

$102

Buy

42.10%

Upside

Reiterated

02/08/26

Boston Scientific: Multi-Year Double-Digit Growth Outlook Makes Share Pullback a Buy Opportunity

Richard Newitter

Truist Financial

$120→$95

Buy

32.35%

Upside

Reiterated

02/05/26

Analysts Conflicted on These Healthcare Names: Eli Lilly & Co (NYSE: LLY), McKesson (NYSE: MCK) and Boston Scientific (NYSE: BSX)

Anthony Petrone

Mizuho Securities

$140→$115

Buy

60.21%

Upside

Reiterated

02/05/26

Boston Scientific price target lowered to $115 from $140 at MizuhoBoston Scientific price target lowered to $115 from $140 at Mizuho

David Rescott

Robert W. Baird

$118→$101

Buy

40.71%

Upside

Reiterated

02/05/26

Boston Scientific price target lowered to $101 from $118 at BairdBoston Scientific price target lowered to $101 from $118 at Baird

Larry Biegelsen

Wells Fargo

$125→$94

Buy

30.96%

Upside

Reiterated

02/05/26

Wells Fargo Sticks to Its Buy Rating for Boston Scientific (BSX)

Vijay Kumar

Evercore ISI

$112→$96

Buy

33.74%

Upside

Reiterated

02/05/26

Boston Scientific price target lowered to $96 from $112 at Evercore ISIBoston Scientific price target lowered to $96 from $112 at Evercore ISI

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Boston Scientific

3 Months

xxx

Success Rate

18/24 ratings generated profit

Average Return

+5.73%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +5.73% per trade.

1 Year

Jayson BedfordRaymond James

Success Rate

41/54 ratings generated profit

Average Return

+14.96%

a rating ―

Copying Jayson Bedford's trades and holding each position for 1 Year would result in 75.93% of your transactions generating a profit, with an average return of +14.96% per trade.

2 Years

xxx

Success Rate

43/54 ratings generated profit

Average Return

+30.13%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 79.63% of your transactions generating a profit, with an average return of +30.13% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0HOY Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0HOY has received 58 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0HOY average Analyst price target in the past 3 months is 108.38.

Each month's total comprises the sum of three months' worth of ratings.

0HOY Financial Forecast

0HOY Earnings Forecast

Next quarter’s earnings estimate for 0HOY is $0.79 with a range of $0.78 to $0.85. The previous quarter’s EPS was $0.80. 0HOY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year 0HOY has Performed in-line its overall industry.

0HOY Sales Forecast

Next quarter’s sales forecast for 0HOY is $5.18B with a range of $5.07B to $5.28B. The previous quarter’s sales results were $5.29B. 0HOY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year 0HOY has Performed in-line its overall industry.

0HOY Stock Forecast FAQ

What is GB:0HOY’s average 12-month price target, according to analysts?

Based on analyst ratings, Boston Scientific’s 12-month average price target is 108.38.

What is GB:0HOY’s upside potential, based on the analysts’ average price target?

Boston Scientific has 50.99% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Boston Scientific a Buy, Sell or Hold?

Boston Scientific has a consensus rating of Strong Buy, which is based on 22 buy ratings, 0 hold ratings and 0 sell ratings.

What is Boston Scientific’s share price target?

The average share price target for Boston Scientific is 108.38. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $132.00 ,and the lowest forecast is $94.00. The average share price target represents 50.99% Increase from the current price of $71.78.

What do analysts say about Boston Scientific?

Boston Scientific’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of Boston Scientific?

To buy shares of GB:0HOY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Boston Scientific (0HOY) Share Forecast & Price Target

0HOY Analyst Ratings

0HOY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Boston Scientific

0HOY Analyst Recommendation Trends

0HOY Financial Forecast

0HOY Earnings Forecast

0HOY Sales Forecast

0HOY Stock Forecast FAQ

Detailed List of Analyst Forecasts